What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “HMBD-001 is a humanized Immunoglobulin G1 (IgG1) anti-Human Epidermal Growth Factor Receptor 3(HER3) monoclonal antibody (mAb). It is administered intravenously (IV) weekly”In the company’s words, NCT05910827 on ClinicalTrials.gov
- Tested for
- Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Esophageal Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Nasopharyngeal Cancinoma (NPC), Squamous Cell Carcinoma, Non-Small Cell Lung Cancer and 3 more
- Main trialPhase 1/2
- “This is a Phase Ib/II multi-center, open-label study of HMBD-001 in combination with cetuximab with or without docetaxel in participants with advanced Squamous Cell Cancers”In the company’s words, NCT05910827 on ClinicalTrials.gov
Other drugs for Advanced Head and Neck Squamous Cell Carcinoma
- APG-157Aveta Biomics, Inc. · Phase 3
- GotistobartOncoC4 · BioNTech · Phase 1/2
- ZanidatamabJazz Pharmaceuticals · Phase 2
- LCB84LigaChem Biosciences, Inc. · Phase 1/2
- PembrolizumabMerck & Co. · Phase 2
- EntrectinibRoche · Phase 1/2
Coming up2
- 1 Dec 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 1 Mar 2031Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 1 Dec 2027 | A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers | |
| Phase 1Active, not recruiting | 1 Mar 2031 | Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026